ANDOVER, Mass., March 5 /PRNewswire-FirstCall/ -- Smith & Nephew's Endoscopy Division today announced the launch of the BIORAPTOR 2.3 PK Suture Anchor for repair of instability in the hip or shoulder joint. The device is featured at Smith & Nephew Endoscopy's booth at the American Academy of Orthopedic Surgery 75th annual meeting in San Francisco, Calif.
Joint instability results when trauma or overuse causes the labrum, or fibrous cartilage lip that runs along the rim of the socket in the shoulder or hip, to stretch or tear. In the shoulder, labral damage often leads to dislocation or subluxation (partial dislocation), which can be painful and limit range of motion. In the hip, it can trigger a clicking or snapping sensation painful enough to be disabling. In both joints, the misalignment that results from labral tears can lead to osteoarthritis.
Smith & Nephew's BIORAPTOR 2.3 PK anchor is designed to be implanted in the dense bone along the rim of the joint socket. Its small size and design provide strong fixation and allow a surgeon to use more than one to establish multiple attachment points, creating a uniform bumper and stabilizing the joint.
The BIORAPTOR 2.3 PK anchor comes with a delivery system that enables surgeons to place it through a portal, or percutaneously (through the skin).
"The new BIORAPTOR system allows me to precisely place the anchors exactly where I want them to be," said Mr. Damian Griffin, a hip specialist and Professor of Trauma and Orthopaedic Surgery at the University of Warwick in the UK. "Working through the portal, it can be difficult to place the anchor properly. With the ability to use a percutaneous approach, I can hit the rim at the precise angle I want."
Dr. Gary M. Gartsman, a shoulder specialist at Texas Orthopedic Hospital in Houston, said the BIORAPTOR 2.3 PK anchor is the "perfect size for capsular stabilization. It holds well, and I am able to insert it at the oblique angle that is often necessary in Bankart repairs."
The BIORAPTOR 2.3 PK Suture Anchor is the second in Smith & Nephew Endoscopy's family of BIORAPTOR suture anchors. The BIORAPTOR 2.9 Suture Anchor, released in 2004, was designed for use in the shoulder, and later adapted for the hip, one of the most challenging joints to access and repair.
"The numbers of surgeons performing hip and shoulder instability repair arthroscopically is climbing, thanks to the development of tools and techniques such as the BIORAPTOR 2.3 Anchor that make these procedures less traumatic to the patient, and less labor-intensive for the practitioner," said Joe Darling, General Manager and Senior VP of Smith & Nephew Endoscopy's Arthroscopic Repair business unit.
(TM)Trademark of Smith & Nephew. Certain Marks Reg. U.S. Pat. & T.M. Off.
Smith & Nephew is a global medical technology business, specialising in Orthopaedic Reconstruction, Orthopaedic Trauma and Clinical Therapies, Endoscopy and Advanced Wound Management products. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopaedics companies.
Smith & Nephew is dedicated to helping improve people's lives. The Company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The Company operates in 32 countries around the world. Annual sales in 2007 were nearly $3.4 billion.
This press release contains certain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. In particular, statements regarding planned growth in our business and in our operating margins discussed under "Outlook" are forward-looking statements as are discussions of our product pipeline. These statements, as well as the phrases "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions, are generally intended to identify forward-looking statements. Such forward- looking statements involve known and unknown risks, uncertainties and other important factors (including, but not limited to, the outcome of litigation and regulatory approvals) that could cause the actual results, performance or achievements of Smith & Nephew, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20F, for a discussion of certain of these factors.
All forward-looking statements in this press release are based on information available to Smith & Nephew as of the date hereof. All written or oral forward-looking statements attributable to Smith & Nephew or any person acting on behalf of Smith & Nephew are expressly qualified in their entirety by the foregoing. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement contained herein to reflect any change in Smith & Nephew's expectation with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
CONTACT: Joe Metzger, Vice President, Corporate Communications of Smith &
Nephew Endoscopy, +1-978-749-1330, firstname.lastname@example.org
Web site: http://www.smith-nephew.com/